Sector News

Novo snaps up two US biotechs

August 31, 2015
Life sciences

Novo Nordisk is bringing two privately-held US biotechs under its wing to expand its reach in diabetes and obesity and gain a stronger foothold in the country.

The Danish drugmaker said it is acquiring Indiana-based Calibrium LLC and MB2 LLC, both of which are relatively fresh on the scene and working on drug targets for diabetes and metabolic diseases.

Calibrium is focused on novel peptides and MB2 LLC on first-in-class, mixed agonist drugs. “I’m optimistic that together we can create novel, transformative therapies in the fight against the global epidemic of diabetes and obesity,” said Richard DiMarchi, chief scientific officer and co-founder of both Calibrium and MB2, commenting on the deal.

The closing of the transaction, which is subject to US regulatory approval, is expected during the third quarter of 2015. Financial details are being kept under wraps.

$2bn investment
The news came just a day after Novo announced plans to invest $2 billion over the next five years in ramping up production in Denmark and the US, to meet global demand for its medicines.

Close to 700 new production and engineering jobs will be generated in Clayton, North Carolina, where the firm already employs more than 700 people, while a new production facility in Måløv, Denmark, for tableting and packaging of oral semaglutide and future oral products, will create around 100 new positions.

By Selina McKee

Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach